Press Release Source: ImmuCell Corporation On Thursday June 9, 2011, 8:00 am EDT
PORTLAND, ME--(Marketwire - 06/09/11) - ImmuCell Corporation (NASDAQ:ICCC - News) today announced that the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA) has accepted the pivotal Nisin residue data in milk and has assigned a zero milk discard time and zero meat withdrawal period. These 'claims' are subject to obtaining the Human Food Safety (HFS) Technical Section Complete Letter and ultimately approval of the New Animal Drug Application (NADA).
Mast Out® is an intramammary treatment for subclinical mastitis in lactating dairy cattle. The remaining element of the HFS Technical Section is the submission to and acceptance by the FDA of ImmuCell's Nisin residue method in milk to measure Nisin concentrations around the newly assigned tolerance limit.
'Zero Discard' means that there would be no requirement to discard milk during treatment or for a period of time thereafter. ImmuCell management believes that this would be a significant competitive advantage differentiating Mast Out® from all other intramammary antibiotics. Market acceptance of this novel product, as a tool capable of revolutionizing the way that mastitis is treated, is critically dependent upon achieving this zero milk discard claim.
"The ruling -- second in importance only to effectiveness -- provides renewed impetus to achieve approval as quickly as possible," commented Dr. Joseph H. Crabb, Vice President and Chief Scientific Officer.
Currently, the FDA is taking a closer look at antibiotic residues in all food products, while global markets are demanding milk products with lower somatic cell counts, indicative of infection status. This market environment may be favorable to the launch of a product like Mast Out®.
About ImmuCell:
ImmuCell Corporation's (NASDAQ:ICCC - News) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (http://www.immucell.com).
Recent ICCC News
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 • GlobeNewswire Inc. • 04/09/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 06:55:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:05:32 PM
- ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 • GlobeNewswire Inc. • 02/27/2024 09:05:00 PM
- ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 • GlobeNewswire Inc. • 02/16/2024 02:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:05:32 PM
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023 • GlobeNewswire Inc. • 01/08/2024 09:05:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 08:22:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:05:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:05:46 PM
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023 • GlobeNewswire Inc. • 11/13/2023 09:05:00 PM
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023 • GlobeNewswire Inc. • 11/07/2023 05:15:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:05:21 PM
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023 • GlobeNewswire Inc. • 10/05/2023 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2023 04:25:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2023 06:49:33 PM
- ImmuCell Announces Submission of CMC Technical Section to the FDA • GlobeNewswire Inc. • 08/29/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:05:44 PM
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023 • GlobeNewswire Inc. • 08/10/2023 08:05:00 PM
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023 • GlobeNewswire Inc. • 08/07/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/21/2023 01:04:28 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/13/2023 06:28:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2023 08:05:21 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM